LETTER TO THE EDITOR

WILEY

Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply

We appreciate the comments made about our study in the Letter from Dong et al. 1,2

Regarding the potential impact of infection on serum ammonia levels or patients' outcomes, in our derivation cohort of ACLF patients, we found no association between infection (vs other reason for intensive care unit (ICU) admission) and ICU days 1 (113 vs. $108 \mu mol/L; p=0.30$) or 2 (85 vs. 91 $\mu mol/L; p=0.49$) serum ammonia levels. Furthermore, there was also no association between infection (vs other reason for ICU admission) and all-cause hospital mortality (37.3% vs. 32.9%; p=0.31). These data suggest that infection per se may not be as influential as other factors, namely liver failure, for serum ammonia levels or outcomes in ACLF patients. Unfortunately, we had no data to assess the potential differential impact of the type of infecting microorganisms, namely urease-producing bacteria, on serum ammonia levels or patients' outcomes. While our study was not aimed at studying such specifics, we acknowledge that further characterising infecting microorganisms could be interesting.³⁻⁵

Concerning the impact of kidney dysfunction on serum ammonia levels or patients' outcomes, in our derivation cohort of ACLF patients, we found no association between ICU day one serum creatinine and ICU days 1 (p=0.85) or 2 (p=0.08) serum ammonia levels. Nevertheless, as shown in our original manuscript, higher median ICU day one serum creatinine was associated with higher all-cause hospital mortality (1.98 vs. 1.32 mg/ dL; p < 0.001). These data suggest that kidney dysfunction per se may not be as relevant as other factors, such as liver failure, for serum ammonia levels in ACLF patients. Unfortunately, we were not able to capture chronic kidney disease (CKD) or acute kidney injury (AKI) occurrence properly due to centre-specific registry limitations, mainly related to prior to hospital stay serum creatinine levels (steady state or baseline, respectively) availability. However, in our derivation cohort of ACLF patients, kidney dysfunction, inferring from ICU day one serum creatinine levels, was associated with mortality. In fact, this is in agreement with the extensive literature describing the deleterious impact of kidney dysfunction on these patients' outcomes.^{6,7}

AP&T correspondence columns are restricted to invited editorials and letters discussing papers that have been published in the journal. An invited editorial or letter must have a maximum of 500 words, may contain one table or figure, and should have no more than 10 references. It should be submitted electronically to the Editors via http://mc.manuscriptcentral.com/apt.

In conclusion, in our multicentre cohort of ACLF patients, neither infection nor kidney dysfunction per se significantly affected early serum ammonia levels.

FUNDING INFORMATION

FSC was supported by the Canadian Association for the Study of the Liver-the Canadian Liver Foundation. SMB was supported by a Canada Research Chair in Critical Care Outcomes and Systems Evaluation.

AUTHOR CONTRIBUTIONS

Filipe S. Cardoso: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead). Minjee Kim: Data curation (equal); writing – review and editing (equal). Rui Pereira: Data curation (equal); writing – review and editing (equal). Luís Bagulho: Data curation (equal); writing – review and editing (equal). Pedro Fidalgo: Writing – review and editing (equal). Anna Pawloski: Writing – review and editing (equal). Richard Wunderink: Writing – review and editing (equal). Nuno Germano: Writing – review and editing (equal). Sean Bagshaw: Supervision (equal); writing – review and editing (equal). Juan G Abraldes: Formal analysis (equal); supervision (equal); writing – review and editing (equal). Constantine Jason Karvellas: Conceptualization (equal); data curation (equal); formal analysis (equal); supervision (equal); writing – review and editing (equal).

ACKNOWLEDGEMENTS

Declaration of personal interests: The Canadian Association for the Study of the Liver -The Canadian Liver Foundation for supporting Dr. Filipe S. Cardoso hepatology fellowship. The authors' declarations of personal and financial interests are unchanged from those in the original article.²

CONFLICT OF INTEREST STATEMENT

None to be declared.

PATIENT CONSENT STATEMENT

Local ethics committees waived the need for individual informed consent (#CES371_2016, 16/12/2016, Central Lisbon University Hospital Center Ethics Committee; Pro00035429, 04/02/2013, University of Alberta Health Research Ethics Board; STU00204868, Northwestern University Institutional Review Board, 08/11/2017).

AUTHORSHIP

Guarantor of the article: Filipe S. Cardoso.

LINKED CONTENT

This article is linked to Cardoso et al papers. To view these articles, visit https://doi.org/10.1111/apt.17650 and https://doi.org/10.1111/apt.17698

Filipe S. Cardoso¹ Minjee Kim² Rui Pereira³ Luís Bagulho⁴ Pedro Fidalgo⁵ Anna Pawlowski⁶ Richard Wunderink⁶ Nuno Germano³ Sean M. Bagshaw⁷ Juan G. Abraldes⁸ Constantine J. Karvellas⁹

¹Transplant Unit and Intensive Care Unit, Curry Cabral Hospital, Nova Medical School, Lisbon, Portugal ²Division of Neurocritical Care, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA ³Intensive Care Unit, Curry Cabral Hospital, Nova Medical

School, Lisbon, Portugal

⁴Transplant Unit and Intensive Care Unit, Curry Cabral Hospital, Lisbon, Portugal

⁵Intensive Care Unit, São Francisco Xavier Hospital, Lisbon, Portugal

⁶Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

⁷Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Canada

⁸Liver Unit, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Canada ⁹Department of Critical Care Medicine, Liver Unit, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Canada Correspondence Filipe S. Cardoso, Curry Cabral Hospital, Central Lisbon University Hospital Center, R Beneficiencia N8, Lisbon 1050-099, Portugal. Email: filipe_sousacardoso@hotmail.com

ORCID

Filipe S. Cardoso D https://orcid.org/0000-0002-6221-6435 Juan G. Abraldes D https://orcid.org/0000-0003-3421-937X

AP&T Alimentary Pharmacology & Therapeutics – \mathbf{W}

REFERENCES

- Dong J-J, Zhang Q-Y, Cai Y-J. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Aliment Pharmacol Ther. 2023;58:960–1.
- Cardoso FS, Kim M, Pereira R, Bagulho L, Fidalgo P, Pawlowski A, et al. Early serum ammonia variation in critically ill patients with cirrhosis: a multicentre cohort study. Aliment Pharmacol Ther. 2023;58(7):715-24.
- Richardson AJ, McKain N, Wallace RJ. Ammonia production by human faecal bacteria, and the enumeration, isolation and characterization of bacteria capable of growth on peptides and amino acids. BMC Microbiol. 2013;13:6.
- Kim M, Cardoso FS, Pawlowski A, Wunderink R, Ladner DP, Abraldes JG, et al. The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study. Hepatol Commun. 2023;7(2):e0038.
- Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022;76(2):332–42.
- Cardoso FS, Abraldes JG, Sy E, Ronco JJ, Bagulho L, Mcphail MJ, et al. Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. Liver Int. 2019;39(7):1271–80.
- Napoleone L, Solé C, Juanola A, Ma AT, Carol M, Pérez-Guasch M, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: relationship with kidney and patients' outcome. Hepatol Commun. 2022;6(8):2121–31.